Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate the antihypertensive effect of amiloride added to triple antihypertensive therapy in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)
The primary objective of this study was to evaluate the antihypertensive effect of amiloride added to triple antihypertensive treatment in patients with resistant hypertension and type 2 diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional study.
The secondary objectives were to evaluate the additional effects of amiloride on:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Amiloride | Experimental | This is a non-randomized and non-controlled study with only one treatment arm with amiloride. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amiloride | Drug | 5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg. |
| Measure | Description | Time Frame |
|---|---|---|
| average daytime systolic and diastolic blood pressure | ambulatory blood pressure monitoring was performed at baseline and after 8 weeks intervention with amiloride | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Urinary albumin excretion | Urine albumin was measured at baseline and after 8 weeks of amiloride treatment. | after 8 weeks |
| plasma potassium | plasma potassium tend to increase during amiloride treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ib A Jacobsen, DMSc | Odense University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sydvestjysk Hospital, Esbjerg | Esbjerg | Denmark | ||||
| Sygehus Lillebaelt. |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24107738 | Background | Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013 Oct;31(10):2094-102. doi: 10.1097/HJH.0b013e3283638b1a. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000584 | Amiloride |
| ID | Term |
|---|---|
| D011719 | Pyrazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| after 4 and 8 weeks |
| urinary urokinase plasminogen activator (uPA) activity | uPA exist in urine where it cleaves plasminogen to plasmin. uPA is possible secreted fra the tubulus cells | At baseline and after 8 weeks of amiloride treatment |
| urine plasminogen and plasmin | U-plasminogen is filtered to urine in patients with microalbuminuria. In urine plasminogen is activated to plasmin by urokinase plasminogen activator.Plasmin activates the epithelial sodium channel. | at baseline and after 8 weeks of amiloride treatment |
| Fredericia |
| Denmark |
| Steno Diabetes Center | Gentofte Municipality | Denmark |
| Odense University Hospital, Department of Endocrinology | Odense | Denmark |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |